Loading…
Loading…
Base rate computed from analyst-asserted responds_to: edges in the reverse direction (target-country → issuer-country) for prior issuer-actions on the same target. Modal type + lag percentiles only — not a model output. Treat as a historical anchor for sizing counter-response scenarios, not a forecast in itself.
The Australia Group (AG) is the 43-member multilateral export-control regime targeting precursor chemicals, biological agents, and dual-use equipment that could contribute to chemical or biological weapons programmes. AG decisions are reached by consensus at annual plenary meetings; member states then transpose the agreed control-list changes into their national export-control regulations. This BIS rule does that transposition for the United States, implementing items adopted at the 2023 plenary (held July 2023, Paris) and the 2024 plenary (held September 2024, Paris).
New ECCN 2B352.k — automated peptide synthesizers. This is the headline addition. It controls instruments that are partly or entirely automated and capable of generating peptides at a "system-synthesis scale" of 1 mmol or greater per run, plus specially-designed software and components. The 1 mmol threshold is calibrated to capture machines large enough for production-scale runs of toxin-relevant peptides while exempting research-bench-scale units. The control finalises an April 2023 BIS unilateral proposed rule (RIN 0694-AJ45) under Section 1758 of the Export Control Reform Act, which BIS held in proposed form pending AG plenary consensus — that consensus arrived at the 2024 plenary, allowing the control to be issued multilaterally rather than as a US-only carve-out.
Chemical and biological list additions. Dipropylamine is added as 1C350.d.11 (CW Schedule 3 precursor); neosaxitoxin is added as 1C351.d.12 (a marine paralytic shellfish toxin structurally adjacent to saxitoxin which was already controlled). The botulinum toxin entry is broadened from "botulinum toxins" to "botulinum neurotoxins" to capture all seven serotypes (A–G) and engineered variants, closing a definitional gap.
Definition and equipment refinements. ECCN 2B351.a (toxic-gas monitors) gets a "minimum detection limit" definition that lowers the practical control threshold by clarifying ambiguity; ECCN 2B352.c (centrifugal separators) is revised to explicitly include single-use disposable separators, which had become commercially prevalent since the entry was last amended.
License requirements. All listed items carry CB (Chemical/ Biological) license requirements for export to all destinations except AG member states; AT (Anti-Terrorism) requirements apply to E:1/E:2 destinations (Cuba, Iran, North Korea, Syria); CW (Chemical Weapons Convention) requirements apply to non-state-party destinations. License-application policy is presumption of denial for end-uses that could contribute to CBW programmes.
synthesizer manufacturers (CEM, Gyros Protein Technologies, Biotage, Activotec, CSBio, AAPPTec) now face license requirements for shipments at the 1 mmol-and-above scale to non-AG destinations including China, Russia, Iran, and most of MENA. CDMO peptide-API capacity in China (e.g. WuXi AppTec / WuXi Biologics, Bachem JV partners) is the largest non-AG-resident market.
September 2024 AG plenary consensus and the December 2024 final rule is fast for BIS — most AG implementations take 18-24 months — reflecting the prior April 2023 proposed-rule scaffolding.
16 January 2025 BIS interim final rule creating ECCN 3A069/3E069 for high-parameter flow cytometers and top-down proteomics mass spectrometers (filed as 2025-01-16-us-bis-biotech-laboratory- equipment-controls). Both reflect a deliberate widening of the US biological dual-use perimeter beyond traditional pathogen/ toxin lists into upstream characterisation and synthesis tooling.
benchtop hardware capability scales — vendors have already signalled R&D toward higher-yield small-footprint units.
will mirror the peptide-synthesizer control on the same timeline; transposition lags create temporary regulatory arbitrage windows.
Israel) will continue to benefit from streamlined-license treatment under existing US-bilateral frameworks despite the formal multilateral upgrade.